<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7813721\results\search\disease\results.xml">
  <result pre="caregivers in seven (50%). For two products [gadoversetamide and split" exact="influenza" post="virus inactivated, containing antigen equivalent to A/California/07/2009 (H1N1)-derived strain"/>
  <result pre="11 were still authorised and three [gadoversetamide, ferumoxytol, and split" exact="influenza" post="virus inactivated, containing antigen equivalent to A/California/07/2009 (H1N1)-derived strain"/>
  <result pre="therapy Unintended (accidental) exposure PandemrixÂ©, GlaxoSmithKline Biologicals S.A., Belgium [split" exact="influenza" post="virus inactivated, containing antigen equivalent to A/California/07/2009 (H1N1)-derived strain"/>
  <result pre="of clinical practice 87 Thromboembolic events Post therapy reoccurrence of" exact="thrombocytopenia" post="Potential for increase in bone marrow reticulin formation Haematological"/>
  <result pre="for indacaterol maleate, which was authorised only for use in" exact="chronic obstructive pulmonary disease," post="and had aRMMs to reduce the risks associated with"/>
 </snippets>
</snippetsTree>
